FDA Delays OPKO Drug Approval Due to Catalent Inspection Issues

Apr 01, 2016

The U.S. FDA has issued a complete response letter (CRL) to OPKO Health's New Drug Application for Rayaldee.

Normally, the FDA issues complete response letters to drug companies to communicate the decision that an NDA or ANDA will not be approved in its present form. However, in this case, the letter was based entirely on deficiencies observed at Catalent -- the CMO enlisted to manufacture Rayaldee.

The FDA noted that observations of deficiencies at Catalent's Florida facility were issued on March 25, 2016 as a result of an FDA field inspection initiated on March 14, 2016

OPKO is seeking approval for Rayaldee as a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

Read the OPKO press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments